USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: MYCOLOGICS, INC.
City: AURORA
State: CO
Zip+4: 80045
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $899,576.00 10
SBIR Phase II $746,420.00 1
STTR Phase I $201,949.00 2

Award List:

N/A

Award Year / Program / Phase: 1999 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $746,420.00

N/A

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $0.00

A NOVEL ANTIFUNGAL COMPOUND FROM CAYENNE PEPPER

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Claude P. Selitrennikoff
Award Amount: $99,582.00
Abstract:
DESCRIPTION (Adapted from the application): Deep-seated mycoses are being increasingly observed in immunocompromised patients and in patients receiving aggressive cancer chemotherapy. The use of available drugs for the treatment of these infections is limited by toxicity and… More

A NOVEL SCREEN FOR INHIBITORS OF FUNGAL GPI-ANCHORING

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Claude P. Selitrennikoff
Award Amount: $100,000.00
Abstract:
Perhaps the most striking difference between fungal cells and human cells is that fungal cells are encased in a wall that protects them from a hostile external environment. The cell wall plays a dynamic role in all aspects of fungal physiology. The fact that human cells lack a cell wall and the… More

The glyoxylate cycle as a new target for antifungals

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Claude P. Selitrennikoff
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): Fungi cause a wide spectrum of disease states. The most common examples are relatively minor, localized infections of the skin and mucous membranes such as athlete's foot, vaginal yeast infections, and infections of keratinized nails. However, an ominously… More

Antifungal drugs: Beta(1,6)-glucan synthesis inhibitors

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Claude P. Selitrennikoff
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): Fungi cause a wide spectrum of disease states. The most common examples are relatively minor, localized infections of the skin and mucous membranes such as athlete's foot, vaginal yeast infections, and infections of keratinized nails. However, an ominously… More

Inhibitors of transcription of fungal glucan synthase

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Claude P. Selitrennikoff
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): Perhaps the most striking difference between fungal cells and human cells is that fungal cells are encased in a wall that protects them from an osmotically and immunologically hostile external environment. In addition, the fungal cell wall relays signals for… More

A novel yeast vaccine against Coccidioides Immitis

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Claude P. Selitrennikoff
Award Amount: $99,997.00
Abstract:
DESCRIPTION (provided by applicant): Coccidioidomycosis, also known as San Joaquin Valley Fever, is a fungal disease caused by Coccidioides immitis that is endemic in portions of Southern Arizona, central California, southern New Mexico and west Texas. The migration of not only permanent residents,… More

A novel vaccine for Aspergillus fumigatus

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Claude P. Selitrennikoff
Award Amount: $99,997.00
Abstract:
DESCRIPTION (provided by applicant): Aspergillus fumigatus is a ubiqutous spore-bearing fungus that causes multiple diseases in humans. These include allergic pulmonary asthma, aspergillomas, and invasive disease of hosts usually with predisposing underlying conditions. For example, in the United… More

New drugs for the treatment of leishmaniasis

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Claude P. Selitrennikoff
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): Leishmania are typanosomatid protozoans that are transmitted by phlebotomine sand flies causing leishmaniasis. Leishmaniasis is a zoonosis and affects 12 million people in 88 countries, of which 72 are considered developing countries. It is estimated that 350… More

A novel recombinant vaccine against Cryptococcus.

Award Year / Program / Phase: 2004 / STTR / Phase I
Agency: HHS
Research Institution: ST. LOUIS UNIVERSITY
Principal Investigator: Claude P. Selitrennikoff
Award Amount: $99,999.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Cryptococcus neoformans is an encapsulated pathogenic yeast that causes pulmonary infections and meningoencephalitis in humans and other animals. During the last 20 years, there has been a dramatic increase in the incidence of cryptococcosis throughout the world… More

A novel vaccine against Leishmania

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Claude P. Selitrennikoff
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): Leishmania are typanosomatid protozoans that are transmitted by phlebotomine sand flies causing leishmaniasis. Leishmaniasis affects 12 million people in 88 countries with an estimated 350 million people that are at risk of infection by the different species of… More

Leishmania major nucleoside hydrolase inhibitors

Award Year / Program / Phase: 2007 / STTR / Phase I
Agency: HHS
Research Institution: COLORADO STATE UNIVERSITY
Principal Investigator: Claude P. Selitrennikoff
Award Amount: $101,950.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Leishmania are typanosomatid protozoans that are transmitted by phlebotomine sand flies causing leishmaniasis. Leishmaniasis is a zoonosis and affects 12 million people in 88 countries, of which 72 are considered develo ping countries. It is estimated that 350… More